AI-designed proteins are created in seconds
Australian researchers have, using artificial intelligence, for the first time designed a biological protein that can stop the growth of...
The price of Leqembi needs to be lowered in Japan
A new analysis from Japan's Center for Outcomes...
Merck gears up in lung diseases with giant acquisition
American pharmaceutical giant Merck announced on Wednesday that...
AstraZeneca strengthens gene therapy portfolio with deals worth up to $825 million
AstraZeneca's rare disease subsidiary, Alexion, has entered into...
AlzeCure Pharma: “We have good momentum”
AlzeCure Pharma, which develops small molecule drugs for the treatment of...
Modus Therapeutics CEO comments on latest milestone
Modus Therapeutics has completed recruitment for the first...
BioStock Global Forum 2025 – watch the videos
Investing in biotech – an article series
New announcement from Japan strengthens Medivir's patent portfolio
The Japanese Patent Office has issued a Notice of...
BioStock Investor Pitch: AlzeCure Pharma
Swedish AlzeCure Pharma develops small molecule drug candidates for the treatment of...
In the shadow of the GLP-1 hype: new report criticizes pharmaceutical companies' patent strategies
A new report from the patent organization I-MAK sheds light...
Notes
Mentice consolidates operations to Denver
Bio-Works secures million-dollar order from global pharmaceutical company
OncoZenge receives investment proceeds from Yangtian Bio-Pharmaceutical
Xspray Pharma confirms bioequivalence for XS003
Evaxion converts debt of EUR 3,5 million
Episurf improves results and focuses on the US
Dynavox Group acquires RehaMedia for EUR 5,8 million
NEWSLETTER
Upcoming events
Investing in Life Science
Discover unparalleled opportunities, set in the vibrant heart of Stockholm. This premier event unites forward-thinking investors and business leaders to...
Life Science Summit
The Nordic region's leading forum for early-stage and growth-phase life science companies. The Summit bridges innovation and capital by providing...
Recommended
Trump threatens 200 percent tariffs on pharmaceuticals
AbbVie acquires Capstan Therapeutics for up to $2,1 billion
GLP-1 drugs drive pharmaceutical boom to 2030
FDA introduces fast track for drugs of national importance
Monetization of future royalties increasingly popular
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account
Today's news roundup
